<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365701">
  <stage>Registered</stage>
  <submitdate>28/01/2014</submitdate>
  <approvaldate>5/02/2014</approvaldate>
  <actrnumber>ACTRN12614000135617</actrnumber>
  <trial_identification>
    <studytitle>Uterine fluid lactate dehydrogenase isoenzyme activity profile. Can it be considered  a diagnostic  marker for endometrial cancer?</studytitle>
    <scientifictitle>Uterine fluid lactate dehydrogenase isoenzyme activity profile. Can it be considered  a diagnostic  marker for endometrial cancer?  A prospective controlled clinical trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>3/26  faculty of medicine Alexandria university registration number </secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>endometrial cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>200 Postmenopausal women with one or more episode of vaginal bleeding will be included after signing informed consent.

The transvaginal ultrasonography (TVS ) and uterine fluid sampling for lactate dehydrogenase ( LD ) isoenzyme analysis will be  performed as office examinations taking about 30 minutes on the same setting.

Endometrial thickness will be  classified as &gt;5 mm or &lt;5 mm on TVS.  

 Patients with endometrial thickness &gt;5 mm on TVS will be evaluated with diagnostic curettage, and those with endometrial thickness &lt;5 mm will be  evaluated with office endometrial biopsy usually within one week . LD isoenzyme profile will  subsequently be related to histopathological diagnosis.
</interventions>
    <comparator>n/a</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>diagnostic accuracy of LD isoenzyme activity in post menopausal uterine bleeding for early detection of endometrial cancer compared to histopathological examination of endometrial tissues.</outcome>
      <timepoint> after histopathological examination of endometrial tissues have been completed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>assessment of accuracy of LD isoenzyme activity in endometrial thickness less than and above 5 mm through comparison with histopathological examination of endometrial tissues.</outcome>
      <timepoint>  Immediately after histopathological examination of endometrial tissues have been completed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> females with postmenopausal uterine bleeding 
even one episode of bleeding will be included in the study 
 </inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with recent endometrial sampling.
Current hormone replacement therapy
 Uterine fluid collection at TVS 
 Clinical signs of endometritis </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>power of the study and sample size were calculated through analysis of the incidence of endometrial cancer in postmenopausal bleeding with accepted error of 10 % and comfidence interval 95% </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>8/02/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>15/05/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>alexandria</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>alexandria univerisity </primarysponsorname>
    <primarysponsoraddress>22 elgeish street , elshatby
Alexandria , egypt
21526</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A new test for diagnosis and early detection of endometrial cancer </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ethical committee , faculty of medicine ,alexandria university</ethicname>
      <ethicaddress>Champollion Street

El-Khartoum Square

Azarita Medical Campus alexandria egypt
21526</ethicaddress>
      <ethicapprovaldate>25/12/2013</ethicapprovaldate>
      <hrec>IRB  00007555-fwa no : 00015712</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>ahmed fawzy galal</name>
      <address> Elshatby maternity university hospital port saeed street alexandria Egypt 21526 </address>
      <phone>+201222286962</phone>
      <fax />
      <email>galal_af@yahoo.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ahmed fawzy galal</name>
      <address> Elshatby maternity university hospital port saeed street alexandria Egypt 21526 </address>
      <phone>+201222286962</phone>
      <fax />
      <email>galal_af@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ahmed fawzy galal</name>
      <address> Elshatby maternity university hospital port saeed street alexandria Egypt 21526 </address>
      <phone>+201222286962</phone>
      <fax />
      <email>galal_af@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ahmed fawzy galal</name>
      <address> Elshatby maternity university hospital port saeed street alexandria Egypt 21526 </address>
      <phone>+201222286962</phone>
      <fax />
      <email>galal_af@yahoo.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>